Danae M Hamouda
-
Program Director, Hem/Onc Fellowship
Associate Chief of Clinical Hematology/Oncology
System Director for HemOnc, Medicine , College of Medicine and Life Sciences
Contact Info
Overview
overview
-
I am an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology in the Department of Internal Medicine at the University of Toledo. I am board certified in Internal Medicine (initial: 2016) and Medical Oncology (initial: 2018) participate in maintenance of certification with a state licensure in Ohio.
I joined the faculty of The University of Toledo College of Medicine and Life Sciences in July 2018 after completion of fellowship in Medical Oncology. My education and training prior to joining as faculty include attainment of a Bachelor of Science in Exercise Science (magna cum laude) from the University of Toledo in 2008, attainment of Doctor of Medicine from the University of Toledo in 2013, completion of Internal Medicine Residency at the University of Toledo in 2016, and completion of Medical Oncology Fellowship at the University of Toledo in 2018, during which time I served as the Chief Fellow in 2017 – 2018.
My career focus is in the field of Medical Oncology, with specific interest in Breast Cancer, Lung Cancer, Genetics, and Prevention. My career goal is to improve the lives of people who are affected by cancer, through providing excellent clinical care, producing meaningful research, and educating the medical community. To this end, I am involved in numerous quality initiatives and improvement of patient care through my work as the Associate Chief of Clinical Hematology and Oncology. I am involved in numerous clinical trials, some as Principal Investigator, from phase 1 clinical trials to international cooperative group trials. I am actively engaged in numerous educational activities, from preclinical teaching particularly in my role as the Hem/Onc System Director, to clinical teaching of medical students, residents, and fellows, and community education through outreach at a variety of events. My career and passion as an academic clinical educator has been graciously supported over many years of education and training by the dedication, diligence, mentorship and guidance of many. I am ambitious and passionate about improving the care and outcomes for people who are affected by cancer, through providing excellent patient care, producing meaningful research, and education.
Publications
selected publications
-
Article (Faculty180)
-
2021Adenomatous polyposis coli in cancer and therapeutic implications. Oncol Rev. 15:534.
-
2021BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. Future oncology (London, England). 17:2817-2830.
-
2021
-
2021Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis. American journal of therapeutics.
-
2021The abscopal effect of radiation therapy. Future oncology (London, England). 17:1683-1694.
-
2020Resident Memory T Cells and Their Effect on Cancer. Vaccines. 8.
-
2019Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. Oncology. 97:59-74.
-
2018Primary Small Intestinal Angiosarcoma: Epidemiology, Diagnosis and Treatment. Journal of clinical medicine research. 10:294-301.
-
2015Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. International journal of hematology. 101:594-7.
-
2015The Impact of Geriatricians Compared to General Practitioners in Patients over the Age of 65 in Regards to Quality of Life and Comprehensive Sense of Well-being. Journal of the American Medical Directors Association. 16:B22.
-
2014Skin lesions with Lynch syndrome could represent Muir-Torre syndrome. International journal of colorectal disease. 29:1013-4.
-
-
Article (Web of Science)
-
2021Adenomatous polyposis coli in cancer and therapeutic implications. ONCOLOGY REVIEWS. 15.Full Text via DOI: 10.4081/oncol.2021.534 PMID: 34267890
-
2015Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. INTERNATIONAL JOURNAL OF HEMATOLOGY. 101:594-597.Full Text via DOI: 10.1007/s12185-015-1739-7
-
Case Study (Faculty180)
-
2021"Pegfilgrastim-induced leukoytosis and hyperleukocytosis” . March, 2021, Vol. 8 No. 1.
-
-
Conference Poster (Faculty180)
-
Early Access (Web of Science)
-
2021BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. FUTURE ONCOLOGY.Full Text via DOI: 10.2217/fon-2021-0072 PMID: 34058833
-
2021The abscopal effect of radiation therapy. FUTURE ONCOLOGY.Full Text via DOI: 10.2217/fon-2020-0994 PMID: 33726502
-
-
Letter (Web of Science)
-
2014Skin lesions with Lynch syndrome could represent Muir–Torre syndrome. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 1013-1014.Full Text via DOI: 10.1007/s00384-014-1876-0
-
-
Meeting Abstract (Web of Science)
-
2021A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry.. JOURNAL OF CLINICAL ONCOLOGY. 1031-1031.Full Text via DOI: 10.1200/jco.2021.39.15_suppl.1031
-
2020Dysphagia with Blood Disorder? an Unusual Presentation for Paroxysmal Nocturnal Hemoglobinuria. BLOOD. 9-10.Full Text via DOI: 10.1182/blood-2020-141501
-
2017Conditional survival estimates for patients with plasma cell leukemia: An analysis of the SEER database.. JOURNAL OF CLINICAL ONCOLOGY. e19533-e19533.Full Text via DOI: 10.1200/jco.2017.35.15_suppl.e19533
-
2017Prophylactic anticoagulation to benefit younger patients under 65 years of age with metastatic lung cancer: An analysis of the 2013 Healthcare Cost and Utilization Project (HCUP) data.. JOURNAL OF CLINICAL ONCOLOGY. 6581-6581.Full Text via DOI: 10.1200/jco.2017.35.15_suppl.6581
-
2017Temporal trend in the use of surgery in the management of stage IIIa non-small cell lung cancer (NSCLC) between 2000-2013: A SEER analysis.. JOURNAL OF CLINICAL ONCOLOGY. 8524-8524.Full Text via DOI: 10.1200/jco.2017.35.15_suppl.8524
-
-
Presentation (Faculty180)
-
Review Article (Web of Science)
-
2021Homologous recombination proficiency in ovarian and breast cancer patients. BMC CANCER.Full Text via DOI: 10.1186/s12885-021-08863-9 PMID: 34711195
-
2020Resident Memory T Cells and Their Effect on Cancer. VACCINES.Full Text via DOI: 10.3390/vaccines8040562 PMID: 33019493
-
2019Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. ONCOLOGY. 59-74.Full Text via DOI: 10.1159/000500488 PMID: 31261152
-
Contact
full name
- Danae M Hamouda